Source:http://linkedlifedata.com/resource/pubmed/id/20378752
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
26
|
pubmed:dateCreated |
2010-7-2
|
pubmed:abstractText |
High-level expression of the cytokine receptor-like factor 2 gene, CRLF2, in precursor B-cell acute lymphoblastic leukemia (pB-ALL) was shown to be caused by a translocation involving the IGH@ locus or a deletion juxtaposing CRLF2 with the P2RY8 promoter. To assess its possible prognostic value, CRLF2 expression was analyzed in 555 childhood pB-ALL patients treated according to the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster 2000 (ALL-BFM 2000) protocol. Besides CRLF2 rearrangements, high-level CRLF2 expression was seen in cases with supernumerary copies of the CRLF2 locus. On the basis of the detection of CRLF2 rearrangements, a CRLF2 high-expression group (n = 49) was defined. This group had a 6-year relapse incidence of 31% plus or minus 8% compared with 11% plus or minus 1% in the CRLF2 low-expression group (P = .006). This difference was mainly attributable to an extremely high incidence of relapse (71% +/- 19%) in non-high-risk patients with P2RY8-CRLF2 rearrangement. The assessment of CRLF2 aberrations may therefore serve as new stratification tool in Berlin-Frankfurt-Münster-based protocols by identifying additional high-risk patients who may benefit from an intensified and/or targeted treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1528-0020
|
pubmed:author |
pubmed-author:AkasakaTakashiT,
pubmed-author:CarioGunnarG,
pubmed-author:DyerMartin J SMJ,
pubmed-author:GeskStefanS,
pubmed-author:HarbottJochenJ,
pubmed-author:IzraeliShaiS,
pubmed-author:MoerickeAnjaA,
pubmed-author:RomeyRenjaR,
pubmed-author:SchrappeMartinM,
pubmed-author:SchrauderAndréA,
pubmed-author:SiebertReinerR,
pubmed-author:StanullaMartinM,
pubmed-author:VaterIngaI,
pubmed-author:ZimmermannMartinM
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
115
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5393-7
|
pubmed:meshHeading |
pubmed-meshheading:20378752-Child,
pubmed-meshheading:20378752-Gene Expression Regulation, Leukemic,
pubmed-meshheading:20378752-Humans,
pubmed-meshheading:20378752-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:20378752-Prognosis,
pubmed-meshheading:20378752-Receptors, Cytokine,
pubmed-meshheading:20378752-Receptors, Purinergic P2,
pubmed-meshheading:20378752-Treatment Outcome
|
pubmed:year |
2010
|
pubmed:articleTitle |
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
|
pubmed:affiliation |
Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Kiel, Germany. g.cario@pediatrics.uni-kiel.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|